CPRX Projected Dividend Yield
Catalyst Pharmaceuticals Inc ( NASDAQ : CPRX )Catalyst Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing medicines for patients living with rare diseases. Co.'s main US commercial product is FIRDAPSE® (amifampridine) Tablets 10 mg approved for the treatment of Lambert-Eaton myasthenic syndrome for adults and for children ages six and up. Co. has the US rights to FYCOMPA®(perampanel) CIII, a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat generalized tonic-clonic seizures in people with epilepsy aged 12 and older. 20 YEAR PERFORMANCE RESULTS |
CPRX Dividend History Detail CPRX Dividend News CPRX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |